Opendata, web and dolomites

GlycoMabs SIGNED

Chemoenzymatic glyco-engineering of therapeutic monoclonal antibodies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GlycoMabs project word cloud

Explore the words cloud of the GlycoMabs project. It provides you a very rough idea of what is the project "GlycoMabs" about.

structures    therapeutic    independent    cells    drugs    glycoengineered    fc    fcgriiia    host    fucose    expertise    glycomabs    treatment    mabs    elucidate    laboratory    industry    act    anticancer    obtain    core    domain    clinical    defucosylation    explore    lacking    enzymes    precise    generation    contributes    glycoproteins    approved    engineer    mixture    potency    basis    affinity    biology    glycan    molecular    engineering    altogether    carbohydrate    crystallisable    position    site    grant    protein    reactions    containing    stablished    mechanisms    synthesis    opportunity    career    modulates    arsenal    structure    ema    homogenous    antibodies    chemoenzymatic    tailor    specificity    generate    afucosylated    glycoengineering    active    functions    learning    antibody    monoclonal    biopharmaceutical    residue    igg1    fragment    intersectoral    construct    glycosylated    asn297    homogeneous    enzyme    glycosylation    me    gained    structural    simplify    conserved    secondment    immune    endos    glycoforms    chemical    skills    lack    alfc    strategies    fucosidase    excellent    linked    cancer    igg    effector    mediated    place    biosuperior    commercialized   

Project "GlycoMabs" data sheet

The following table provides information about the project.

Coordinator
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS 

Organization address
address: PARQUE TECNOLOGICO EDIFICIO 801 A
city: DERIO VIZCAYA
postcode: 48160
website: www.cicbiogune.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 160˙932 €
 EC max contribution 160˙932 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2019
 Duration (year-month-day) from 2019-04-16   to  2021-04-15

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS ES (DERIO VIZCAYA) coordinator 160˙932.00

Map

 Project objective

Monoclonal Antibodies (mAbs) have gained an important place in the therapeutic arsenal of anticancer drugs. mAbs are glycoproteins containing a conserved N-linked glycosylation site at residue Asn297 of the fragment crystallisable (Fc). Most of the mAbs approved by the EMA are commercialized as a complex mixture of glycoforms at this site. It is well stablished that the precise chemical structure of the N-linked glycan modulates the effector functions mediated by the Fc domain. Specifically, for cancer treatment applications, the lack of fucose on the glycan structure contributes to enhance the effector functions of the antibodies, via increased affinity of IgG1 for FcgRIIIa on immune cells. New strategies to glycoengineering mAbs with homogenous glycoforms and lacking fucose core on their glycan structures have become a priority for the biopharmaceutical industry in order to obtain “biosuperior” anticancer drugs. Here, we will engineer a novel fucosidase enzyme that can act on fully glycosylated mAbs in order to simplify the chemoenzymatic synthesis of antibody drugs, based on the host laboratory expertise in Carbohydrate Active Enzymes. We will address three specific aims: (1) to define the structural basis of EndoS antibody specificity; (2) to elucidate the molecular mechanisms of IgG defucosylation by AlfC; and (3) to engineer an enzyme with fucosidase activity and specific for IgG. The GlycoMabs project will provide me an excellent and unique career opportunity by learning new skills in structural biology, protein engineering and project management which will grant me a leading independent position. Moreover, I will explore the industry interest in the application of our novel enzymes to generate homogeneous and afucosylated antibodies through an intersectoral secondment. Altogether, we will contribute to construct the next generation of therapeutic glycoengineered mAbs to tailor the immune reactions and increase their clinical potency.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLYCOMABS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLYCOMABS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

uTSSreg (2020)

Regulation of mammalian genes by new classes of promoter proximal transcription start sites

Read More  

POMOC (2019)

Charles IV and the power of marvellous objects

Read More